: What investors need to know about Pfizer’s latest downgrade
The company’s pipeline, though promising, is still too premature to make up for the looming drop in COVID-19 franchise revenue.
You might also like
The company’s pipeline, though promising, is still too premature to make up for the looming drop in COVID-19 franchise revenue.
Recover your password.
A password will be e-mailed to you.